KNSA vs. AKRO, SUPN, ARQT, INVA, OCUL, OGN, BBIO, CYTK, APLS, and MDGL
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Akero Therapeutics (AKRO), Supernus Pharmaceuticals (SUPN), Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Ocular Therapeutix (OCUL), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Akero Therapeutics (NASDAQ:AKRO) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Kiniksa Pharmaceuticals' net margin of 0.00%. Akero Therapeutics' return on equity of -7.26% beat Kiniksa Pharmaceuticals' return on equity.
In the previous week, Akero Therapeutics had 10 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 11 mentions for Akero Therapeutics and 1 mentions for Kiniksa Pharmaceuticals. Akero Therapeutics' average media sentiment score of 1.88 beat Kiniksa Pharmaceuticals' score of 0.48 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
Kiniksa Pharmaceuticals received 67 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote while only 61.49% of users gave Akero Therapeutics an outperform vote.
Akero Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
Akero Therapeutics presently has a consensus price target of $41.13, indicating a potential upside of 118.52%. Kiniksa Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 63.07%. Given Kiniksa Pharmaceuticals' higher probable upside, equities research analysts plainly believe Akero Therapeutics is more favorable than Kiniksa Pharmaceuticals.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 7.9% of Akero Therapeutics shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Kiniksa Pharmaceuticals has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Kiniksa Pharmaceuticals beats Akero Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
